AMGEN INC · News & developments
Novartis’ Pelacarsen Failure Raises a New Question for Amgen’s Lp(a) Opportunity
Source: Your Wyoming LinkBearish
Novartis’ pelacarsen missed the goal of its Phase III study. The result prompted concerns about the broader Lp(a)-lowering drug class and its implications for Amgen’s olpasiran program.
Why this matters
A failed competing trial raises clinical and valuation risk for olpasiran because it weakens confidence that Lp(a) reduction will translate into meaningful cardiovascular outcomes. If the class thesis is impaired, Amgen’s potential future revenue opportunity and the probability-weighted value assigned to its pipeline could decline, although the competitive setback could also reduce a direct rival if olpasiran ultimately succeeds.